Overview

Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma

Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
This study evaluated two chemotherapy regimens with and without the addition of interferon in patients with advanced or recurrent melanoma.
Phase:
Phase 3
Details
Lead Sponsor:
National Cancer Institute, Naples
Treatments:
Dacarbazine
Fotemustine
Interferon alpha-2
Interferon-alpha
Interferons